Will Mustang Bio stock go up?

According to Danelfin AI, Mustang Bio has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (48.34%) is -2.49% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Mustang Bio stock?

The Mustang Bio target price is $0.7 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Mustang Bio stock right now?

Mustang Bio has today a Hold rating (AI Score 4/10), according to Danelfin AI. Its probability of beating the market in 3 months (48.34%) is -2.49% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Mustang Bio stock is a good buy .

Is Mustang Bio undervalued right now?

Based on analysts, the average price target downside for Mustang Bio is 0.00% (1Y). According to Danelfin AI, Mustang Bio has today an AI Score of 4/10 (Hold Rating).

What was the price range of Mustang Bio stock over the past 12 months?

The Mustang Bio stock price range over the past 12 months has been $0.6 - $3.34.

What is going on with Mustang Bio stock in the last 3 months?

The Mustang Bio stock performance in the last quarter has been -7.38%.

Does Mustang Bio offer dividend payments?

No, Mustang Bio does not currently pay dividends.

What is the current market capitalization of Mustang Bio?

Mustang Bio's market cap is $5.32M, as of 2026-07-03 08:00.

Mustang Bio Inc (MBIO) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

MBIO AI-Powered Stock Analysis

AI Score Explanation

AI Score

Hold

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Mustang Bio Inc today receives an AI Score of 4/10, which translates to a Hold rating. The stock has a 48% probability of outperforming the market in the next 3 months, which is 3% lower than the average probability of any stock (51%). The top positive contributor is the aggregated impact of technical signals (Technicals Impact Long Tail), which adds +2.84% to the probability. Additionally, low short-term volatility (ATR 14d) in the bottom 10% boosts the probability by +1.29%, and low 90-day volatility (ATR 90d) in the bottom 10% adds +0.87%. On the negative side, the top detractors include low Institutional Ownership in the bottom 20% (-1.21%), a Fear & Greed Index of 31 (indicating fear) (-1.21%), and a Chart Pattern (504d) that reduces probability by -0.88%. High Maximum Volatility in the top 20% (-0.87%) and a high Beta of 2.03 in the top 10% (-0.67%) also weigh on the stock's outlook. Notable data points include a very low Total Common Equity of 8.60 in the bottom 20%, reflecting a weak equity base, and a negative Performance YTD of -28.24% in the bottom 20%, indicating significant year-to-date losses. The stock's high volatility is underscored by a Normalized Average True Range (180d) in the top 10% and a Beta in the top 10%, suggesting it moves much more than the market. While low volatility metrics (ATR 14d and 90d) are positive, the overall picture is mixed: the stock has a low probability of outperforming due to weak fundamentals, high volatility, and negative price trends, balanced by some technical tailwinds. This aligns with the Hold rating, indicating the stock is expected to perform in line with the market.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Momentum+1.79%
Direction and strength of recent price movements
Size & Liquidity+0.28%
Company size and trading liquidity

Sentiment-2.10%
How analysts and the market view the stock
Valuation-0.98%
How the stock is priced relative to its fundamentals
Financial Strength-0.83%
Balance sheet strength and financial resilience
Volatility-0.65%
How much the stock price tends to fluctuate

MBIO probability advantage of beating the market (3M):

-2.49%

AI Score

Hold

Mustang Bio (MBIO) has an AI Score of 4/10 (Hold) because, according to an overall analysis, it has a probability advantage of -2.49% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of MBIO (48.34%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
MBIO probability advantage of beating the market (3M)-2.49%
MBIO probability of beating the market (3M)48.34%

MBIO probability advantage of beating the market (3M): -2.49%

The AI-powered overall analysis of Mustang Bio (MBIO) is based on the 25 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of MBIO:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Technical	Technicals Impact (Long Tail)	-	N/A	+2.84%
Technical	ATR (14d Volatility)	0.07	N/A	+1.29%
Sentiment	Institutional Ownership	6.70%		-1.21%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-1.21%
Technical	Chart Pattern (504d)	figure_6	N/A	-0.88%
Technical	Maximum Volatility	8.78%		-0.87%
Technical	ATR (90d Volatility)	0.13	N/A	+0.87%
Technical	Beta	2.03		-0.67%
Technical	Normalized Average True Range (50d)	9.70%		-0.64%
Fundamental	Total Common Equity	8.6		-0.59%
Fundamental	Upgrade to unlock			-0.55%
Technical	Upgrade to unlock			+0.49%
Technical	Upgrade to unlock			-0.49%
Fundamental	Upgrade to unlock			-0.43%
Technical	Upgrade to unlock			-0.39%

Rest of Alpha Signals: -0.04%

MBIO probability advantage of beating the market (3M)Total:-2.49%
MBIO AI Score

Significant changes Vs previous day

MBIO Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$0.70
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

MBIO Proven Hold Signal & Price Forecast

This is the price chart for MBIO from January 2, 2026 until today. The chart indicates, in yellow, the 110 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

MBIO Average Past Performance & Win Rate

Three months after its 639 Hold signals since July 2026, MBIO had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

639 Past MBIO Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-47.68%
Average Alpha				-63.65%
Win Rate (% Positive Perf.)				5.91%
% Positive Alpha				3.20%

MBIO Frequently Asked Questions

Will Mustang Bio stock go up?
According to Danelfin AI, Mustang Bio has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (48.34%) is -2.49% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Mustang Bio stock?
Is it a good time to buy, sell, or hold Mustang Bio stock right now?
Is Mustang Bio undervalued right now?
What was the price range of Mustang Bio stock over the past 12 months?
What is going on with Mustang Bio stock in the last 3 months?
Does Mustang Bio offer dividend payments?
What is the current market capitalization of Mustang Bio?

Mustang Bio Inc Company Profile

Mustang Bio, Inc. operates as a clinical-stage biopharmaceutical enterprise primarily committed to transforming cutting-edge cell and gene therapies into potential life-saving treatments, targeting hematologic cancers, solid tumors, and obscure genetic diseases. The company's activity compass is primarily directed at launching gene therapy programs aimed at solving rare genetic maladies, launching CAR T engineered cell therapies to take on hematologic malignancies as well as formulating CAR T therapies intended for solid tumors.

At the core of its innovative initiatives are the MB-117 and MB-217 projects. These twin undertakings are precisely focused gene therapy programs geared towards combating X-linked severe combined immunodeficiency - a rare genetic immune deficiency in which affected newborns might not survive beyond infancy without appropriate medical care.

Simultaneously, Mustang Bio Inc. is driving forward with the development of its MB-106 CAR T cell scheme for B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. It's also developing the MB-101 CAR T cell program specifically designed for glioblastomas & MB-108-a new generation oncolytic herpes simplex virus.

Bearing notable licensing agreements with high-profile institutions such as Nationwide Children’s Hospital, CSL Behring, Mayo Clinic, Leiden University Medical Centre, and SIRION Biotech GmbH—evidence of formidable strategic alliances—the company continues advancing its mission.

Incorporated in 2015 with corporate headquarters nestled within Worcester, Massachusetts; Mustang Bio Inc., has truly etched itself into the heart of the biopharmaceutical landscape by concurrently prioritizing innovation and lifesaving advancements.

Sector:Health Care
Country:United States
Industry:Biotechnology
Address:95 Sawyer Rd, Suite 110, Waltham
Employees:4
Website:mustangbio.com

Pros

Proprietary cell and gene therapy platforms

Addressing unmet medical needs in oncology

Potential for orphan drug market exclusivity

High switching costs for successful therapies

Platform technology for multiple indications

Cons

Extremely high capital intensity for clinical trials

Substantial regulatory approval risk for novel therapies

Reliance on intellectual property and licensing agreements

Complex and costly manufacturing processes

Competition from established biopharmaceutical companies

MBIO Stock AI Analysis High Risk

Mustang Bio Inc

MBIO Stock AI Analysis

Mustang Bio Inc

MBIO AI-Powered Stock Analysis

AI Score Explanation

AI Score Explanation

Generating AI Score explanation

AI Score Alpha Factors

Alpha Signals: What Drives the AI Score

MBIO probability advantage of beating the market (3M): -2.49%

MBIO Trading Parameters

MBIO Proven Hold Signal & Price Forecast

MBIO Average Past Performance & Win Rate

MBIO Frequently Asked Questions

Will Mustang Bio stock go up?

What is the target price for Mustang Bio stock?

Is it a good time to buy, sell, or hold Mustang Bio stock right now?

Is Mustang Bio undervalued right now?

What was the price range of Mustang Bio stock over the past 12 months?

What is going on with Mustang Bio stock in the last 3 months?

Does Mustang Bio offer dividend payments?

What is the current market capitalization of Mustang Bio?

Mustang Bio Inc Company Profile

Pros

Cons

Pros

Cons

MBIO Company Profile Summary

MBIO Related Investment Themes

MBIO Related Stocks

MBIO Top 10 Industry Stocks

Biotechnology

MBIO Top 10 Sector Stocks

Health Care

MBIO Stock AI Analysis High Risk

Mustang Bio Inc

NASDAQ NMS - GLOBAL MARKET

Will Mustang Bio stock go up?

What is the target price for Mustang Bio stock?

Is it a good time to buy, sell, or hold Mustang Bio stock right now?

Is Mustang Bio undervalued right now?

What was the price range of Mustang Bio stock over the past 12 months?

What is going on with Mustang Bio stock in the last 3 months?

Does Mustang Bio offer dividend payments?

What is the current market capitalization of Mustang Bio?

NASDAQ NMS - GLOBAL MARKET

MBIO Proven Hold Signal & Price Forecast

Pros

Cons

AI Score Explanation